Artificial intelligence could revolutionize cell therapy manufacturing, but the industry needs to get better at gathering and handling data according to an expert, who says companies must stop creating silos.
Making a cell therapy is a technically challenging process that combines complicated genetic modification and culturing steps. Each process has variables that must be monitored and controlled.
At present, rather than looking at entire processes, most manufacturers tend to collect and analyze data at each unit operation. While this approach affords control over the processing step in question, it also creates silos that limit data use, says Dalip Sethi, PhD, commercial leader, cell therapy technologies at Terumo Blood and Cell Technologies.
“AI holds significant promise in the cell therapy and biopharma sectors to improve efficiency, reduce waste, cut costs, and…
